Skip to main content
logo
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
25.82
+0.89 (3.57%)
Aug 6, 2026, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical had revenue of $214.00M in the quarter ending June 30, 2026, with 28.14% growth. This brings the company's revenue in the last twelve months to $717.21M, up 17.55% year-over-year. In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth.

Revenue (ttm)
$717.21M
Revenue Growth
+17.55%
P/S Ratio
3.54
Revenue / Employee
$522,976
Employees
1,371
Market Cap
2.54B

Revenue Chart

Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025673.00M113.00M20.18%
Dec 31, 2024560.00M126.00M29.03%
Dec 31, 2023434.00M70.67M19.45%
Dec 31, 2022363.33M11.92M3.39%
Dec 31, 2021351.41M80.38M29.66%
Dec 31, 2020271.03M167.32M161.32%
Dec 31, 2019103.71M52.22M101.41%
Dec 31, 201851.50M48.88M1,871.48%
Dec 31, 20172.61M2.48M1,863.91%
Dec 31, 2016133.00K--
Dec 31, 2015---
Dec 31, 2014---
Dec 31, 2013---
Dec 31, 2012---
Dec 31, 2011---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Tarsus Pharmaceuticals535.08M
Vericel306.30M
Precigen85.72M
Viridian Therapeutics70.92M
Nektar Therapeutics55.63M
Nurix Therapeutics36.77M
Revenue Rankings

RARE News

More News